Imaging Docking and Fusion of Insulin Granules Induced by Antidiabetes Agents
Sulfonylurea and Glinide Drugs Preferentially Mediate the Fusion of Newcomer, but Not Previously Docked, Insulin Granules
- Address correspondence and reprint requests to Shinya Nagamatsu, MD, Department of Biochemistry, Kyorin University School of Medicine, Shinkawa 6-20-2, Mitaka, Tokyo 181-8611, Japan. E-mail: shinya{at}kyorin-u.ac.jp
Abstract
Sulfonylurea and glinide drugs, commonly used for antidiabetes therapies, are known to stimulate insulin release from pancreatic β-cells by closing ATP-sensitive K+ channels. However, the specific actions of these drugs on insulin granule motion are largely unknown. Here, we used total internal reflection fluorescence (TIRF) microscopy to analyze the docking and fusion of single insulin granules in live β-cells exposed to either the sulfonylurea drug glibenclamide or the glinide drug mitiglinide. TIRF images showed that both agents caused rapid fusion of newcomer insulin granules with the cell membrane in both control and diabetic Goto-Kakizaki (GK) rat pancreatic β-cells. However, in the context of β-cells from sulfonylurea receptor 1 (SUR1) knockout mice, TIRF images showed that only mitiglinide, but not glibenclamide, caused fusion of newcomer insulin granules. Compositely, our data indicate that 1) the mechanism by which both sulfonylurea and glinide drugs promote insulin release entails the preferential fusion of newcomer, rather than previously docked, insulin granules, and that 2) mitiglinide can induce insulin release by a mechanism independent of mitiglinide binding to SUR1.
- KATP channel, ATP-sensitive K+ channel
- [Ca2+]i, intracellular Ca2+ concentration
- CCD, charge-coupled device
- GFP, green fluorescent protein
- KRB, Krebs-Ringer buffer
- SUR, sulfonylurea receptor
- TIRF, total internal reflection fluorescence
Footnotes
-
Additional information for this article can be found in an online appendix at http://diabetes.diabetesjournals.org.
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
-
- Accepted June 27, 2006.
- Received January 24, 2006.
- DIABETES
